EILAT XVIII

“Autifony’s participation at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) in May this year where the potential for Kv3 modulators in the treatment of epilepsy was presented by the company and recorded in a special issue of Epilepsia (DOI: 10.1002/epi.70354).”
EILAT XVIII Ms I